FundingMediWound received €16.5 million in funding from the European Innovation Council to accelerate the development of EscharEx in the DFU indication.
Market DemandNexoBrid's US rollout by partner Vericel continues to build momentum, as Vericel reported 1Q revenue increases for the product of 207% year over year and 31% sequentially.
Product DevelopmentEscharEx is a disruptive technology in the ~$2.5B chronic wound care segment, representing a significant market opportunity.